{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:53:34Z","timestamp":1789084414578,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Accurate estimation of kidney function is essential for patient selection and drug dosing in patients with cancer. eGFR equations are necessary for decision making and monitoring. Our aim was to identify which of these equations\u2014estimated creatinine clearance (eCrCl) by Cockcroft-Gault (CG), eGFR by Modification of Diet in Renal Disease (eGFR\n                      <jats:sub>MDRD<\/jats:sub>\n                      ), CKD Epidemiology Collaboration (eGFR\n                      <jats:sub>CKD-EPI<\/jats:sub>\n                      ) or the recently proposed Janowitz-Williams equation (eGFR\n                      <jats:sub>J-W<\/jats:sub>\n                      )\u2014would be most suitable for GFR estimation among patients with cancer receiving cisplatin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assembled a cohort of 5274 patients with cancer treated with cisplatin-based chemotherapy at two large cancer centers. We ascertained the frequency of cisplatin-associated AKI (C-AKI) defined as a \u22650.3 mg\/dl rise in serum creatinine over baseline. We compared baseline eGFR and eCrCl using Bland-Altman (B-A) plots, coefficients of variation (CV), and concordance correlation coefficients. We calculated the positive predictive value (PPV), negative predictive value (PPV), accuracy, and area under the curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients were predominantly middle aged (median 58 years, IQR 49\u201366 years), overweight (median BMI 26.2, IQR 23.1\u201329.8 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and White (88%), with a median baseline creatinine of 0.8 mg\/dl and median cisplatin dose of 99 mg. C-AKI developed in 12% of the cohort. eGFR\n                      <jats:sub>CKD-EPI<\/jats:sub>\n                      had the highest PPV and AUC. eGFR\n                      <jats:sub>CKD-EPI<\/jats:sub>\n                      and eGFR\n                      <jats:sub>MDRD<\/jats:sub>\n                      , along with their BSA-modified counterparts, had the closest agreement with the lowest CV (7.2, 95% CI, 7.0 to 7.3) and the highest concordance. C-AKI was lowest when using eGFR\n                      <jats:sub>CKD-EPI<\/jats:sub>\n                      to define eGFR \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      On the basis of its superior diagnostic performance, eGFR\n                      <jats:sub>CKD-EPI<\/jats:sub>\n                      should be used to estimate GFR in patients being considered for cisplatin-based chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000572020","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T16:30:12Z","timestamp":1609259412000},"page":"205-214","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury"],"prefix":"10.34067","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-3389","authenticated-orcid":false,"given":"Shveta S.","family":"Motwani","sequence":"first","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina D.","family":"Kaymakcalan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Waikar","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Section of Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C.","family":"Curhan","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Channing Division of Network Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11096-013-9912-7","article-title":"Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?","volume":"36","author":"Bennis","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/ndt\/gfs607","article-title":"Moderator\u2019s view: Estimating glomerular filtration rate--the past, present and future","volume":"28","author":"Hallan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","article-title":"Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Matzke","year":"2011","journal-title":"Kidney Int"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"DuBois","year":"1916","journal-title":"Arch Intern Med (Chic)"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jcph.906","article-title":"Population pharmacokinetic analysis of bortezomib in pediatric leukemia patients: Model-based support for body surface area-based dosing over the 2- to 16-year age range","volume":"57","author":"Hanley","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.124","article-title":"Use of the MDRD study equation to estimate kidney function for drug dosing","volume":"86","author":"Stevens","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2010.03.026","article-title":"Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL\/min\/1.73 m2","volume":"56","author":"Stevens","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.ajkd.2012.03.016","article-title":"Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR","volume":"60","author":"Matsushita","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate [published correction appears in Ann Intern Med 149: 519, 2008]","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jnci\/djq216","article-title":"Testicular cancer survivorship: Research strategies and recommendations","volume":"102","author":"Travis","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis","volume":"81","author":"Coca","year":"2012","journal-title":"Kidney Int"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"e0142225","DOI":"10.1371\/journal.pone.0142225","article-title":"Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: An observational cohort study","volume":"10","author":"Bhat","year":"2015","journal-title":"PLoS One"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdv369","article-title":"Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors","volume":"26","author":"Boer","year":"2015","journal-title":"Ann Oncol"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.ajkd.2017.10.005","article-title":"Improving carboplatin dosing based on estimated GFR","volume":"71","author":"Beumer","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365513.2017.1298001","article-title":"Comparison of methods for estimating glomerular filtration rate in head and neck cancer patients treated with cisplatin","volume":"77","author":"Lindberg","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-2966-1","article-title":"Validity of new methods to evaluate renal function in cancer patients treated with cisplatin","volume":"77","author":"Funakoshi","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2011.10.004","article-title":"Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer","volume":"10","author":"Tsao","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"B33-20250825","doi-asserted-by":"crossref","first-page":"e94471","DOI":"10.1371\/journal.pone.0094471","article-title":"CKD-EPI and Cockcroft-Gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"9","author":"Pal","year":"2014","journal-title":"PLoS One"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"141","DOI":"10.34067\/KID.0000952019","article-title":"GFR measurement and chemotherapy dosing in patients with kidney disease and cancer","volume":"1","author":"McMahon","year":"2020","journal-title":"Kidney360"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2020.04.010","article-title":"Performance of indexed and nonindexed estimated GFR","volume":"76","author":"Titan","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000356587","article-title":"The risk factors of severe acute kidney injury induced by cisplatin","volume":"85","author":"Mizuno","year":"2013","journal-title":"Oncology"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"e203639","DOI":"10.1001\/jamanetworkopen.2020.3639","article-title":"Epidemiologic characteristics of acute kidney injury during cisplatin infusions in children treated for cancer","volume":"3","author":"McMahon","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1177\/1078155219901305","article-title":"Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study","volume":"26","author":"Ben Ayed","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/jog.13457","article-title":"Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer","volume":"43","author":"Yamamoto","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"B40-20250825","article-title":"Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma [published online ahead of print may 29, 2020]","author":"Hod","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000572020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:44Z","timestamp":1786478564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000572020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000572020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}